With insulin price cap, drug industry is once again shamed into doing the right thing

Los Angeles Times 

The United States doesn't have a market-based economy for prescription drugs. It has a shame-based economy. The latest example of this Scarlet Letter approach to drug pricing came this week as insurance giant Cigna and its Express Scripts subsidiary announced that consumers with drug benefits managed by the company could see their out-of-pocket costs for insulin limited to $25 a month. "For people with diabetes, insulin can be as essential as air," Steve Miller, Cigna's chief clinical officer, said in a statement. "We need to ensure these individuals feel secure in their ability to afford every fill so they don't miss one dose, which can be dangerous for their health."

Duplicate Docs Excel Report

Title
None found

Similar Docs  Excel Report  more

TitleSimilaritySource
None found